These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
Muscular Dystrophy UK is investing £1.2 million into 9 new research projects this year, bringing our total research portfolio to over £10m.
Scientists from Fred Hutchinson Cancer Research Center (USA) have identified a new role for DUX4, the gene that is mutated in FSHD
The FSH Society International Research Congress was held in France, on 19-20 June 2019
Fulcrum Therapeutics has obtained rights to losmapimod from GSK. Fulcrum is interested in the drug because it has found that it can switch off DUX4 in FSHD cells.
Facio Therapies announced today that it has completed a comprehensive search for new FSHD drug candidates.
A recent study has demonstrated the value of a new mouse model of facioscapulohumeral muscular dystrophy (FSHD).
Facio Therapies has shown that one of its lead compounds can reduce the levels of DUX4 in a mouse model.
Facio Therapies has announced that it has selected several compounds as lead candidates for its FSHD drug development programme.
Acceleron has announced the FDA has granted Orphan Drug Designation to ACE-083 for the treatment of FSHD.
Genea Biocells has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to GBC0905 for the treatment of FSHD.